Adam Feinstein at Barclays Capital says the recent Barron's piece critical of HCA's accounting practices is wide of the mark and that investors should "take advantage on any disruption in the share price resulting from this article." Feinstein has HCA at 'overweight' and sees the stock (Ticker: HCA) going to $30.
The market watchers at Energy Stock Channel say the technical indicators for Delek US Holdings are signaling a bottom. The relative strength of the Brentwood-based company's shares (Ticker: DK) has fallen below 30 after a one-month slide of more than 20 percent.
The analysts at Fitch Ratings have given a B+ to the $500 million hospital giant HCA plans to raise in the coming days. And while that offering and the recent big raise to help HCA buy back Bank of America's stake will lift the company's total debt to 4.8 times EBITDA, Fitch says the pending purchase of the remainder of HealthOne in Colorado will bring that ratio back in line very quickly next year.
Analyst Glen Losev at Auriga USA has launched coverage of hospital industry leader HCA (Ticker: HCA) with a 'buy' rating and a price target of $28. Losev's timing is nice: The firms who came out after (helping manage) HCA's IPO telling investors to keep buying ended up looking pretty silly last month. Losev in July launched coverage of fellow local hospital chains CHS and LifePoint with 'hold' ratings.
Mark Montagna at Avondale says Genesco's strong operating numbers — it doubled analysts' expectations in Q2 — reinforce the idea that fashion trends are focused on footwear right now, which will provide a nice tailwind to the Nashville-based retailer for the foreseeable future. "We continue to believe the relative value advantage of footwear vs apparel will drive footwear outperformance vs apparel in 2H11," he wrote in a recent note raising his price target for Genesco (Ticker: GCO) to $61 from $55.